Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Clinical Pharmacokinetics|August 1, 2018
Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid LeukemiaJennifer Hibma, Beverly Knight
Journal of Clinical Pharmacology|December 17, 2025
Elranatamab Exposure-Safety Analysis in Relapsed or Refractory Multiple MyelomaPooneh Soltantabar, Jennifer Hibma, Diane Wang, et al.
Targeted Oncology|August 20, 2025
Elranatamab Fixed Dosing: A Safe, Effective, and Convenient Dosing ApproachMohamed Elmeliegy, Pooneh Soltantabar, Jennifer Hibma, et al.
Oncology and Therapy|March 2, 2026
Summary of Research: Elranatamab Fixed Dosing-A Safe, Effective, and Convenient Dosing ApproachMohamed Elmeliegy, Pooneh Soltantabar, Jennifer Hibma, et al.
NPJ Systems Biology and Applications|September 1, 2025
Leveraging quantitative systems pharmacology modeling for elranatamab regimen optimization in relapsed or refractory multiple myelomaKamrine E Poels, Mohamed Elmeliegy, Jennifer Hibma, et al.
Pharmaceutics|April 11, 2020
Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of DacomitinibAna Ruiz-Garcia, Weiwei Tan, Jerry Li, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 5, 2023
Case-control matching-guided exposure-efficacy relationship for avelumab in patients with urothelial carcinomaPooneh Soltantabar, Ali Alhadab, Jennifer Hibma, et al.
Clinical Pharmacology and Therapeutics|May 11, 2021
Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung CancerJoseph Chen, Ana Ruiz-Garcia, Leonard P James, et al.
Targeted Oncology|August 18, 2025
Population Exposure-Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple MyelomaHoi-Kei Lon, Jennifer Hibma, Sibo Jiang, et al.
Clinical Pharmacology and Therapeutics|February 16, 2025
A Novel Two-Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma PatientsDonald Irby, Jennifer Hibma, Mohamed Elmeliegy, et al.
Pageof 2